Bachem

Bubendorf, CH
Oligonucleotide
Program data pending ClinicalTrials.gov matching · Last scored 2026-04-02
83.4
Signal Score
✓ FDA Inspections (1) ○ Clinical Trials ○ SEC Filings ✓ Press (14) ○ EMA GMP ○ MHRA GMP

Quick Facts: Bachem

Signal Score
83.4/100 (as of 2026-04-02)
Quality Compliance
98.8/100
Headquarters
Bubendorf, CH
Modalities
Oligonucleotide
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance 98.8
FDA Inspections1 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2024-08-16)
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesOligonucleotide
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 75.0
Publicly traded — financial transparency
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Publicly traded — financial transparency
Capacity 65.0
2 manufacturing sites
Facility expansion news detected
Regulatory milestones (2 articles)
Sites: Bubendorf, Switzerland, Torrance, CA
Source: SEC EDGAR, press monitoring, company profiles
2 manufacturing sites
Recent Press14 articles
2 manufacturing sites
Facility expansion news detected
Regulatory milestones (2 articles)

FDA Inspection History

2024-08
NAI VAI OAI
Date Site Type Observations Classification
2024-08-16 Bubendorf Drug Quality Assurance No Voluntary Action Indicated (VAI)
Source: FDA Data Dashboard · Retrieved Apr 05, 2026

Recent News 14 articles

facility_expansion 2026-03-24
Bachem Holding AG stock faces operational push amid peptide market expansion and biotech demand surg - AD HOC NEWS
Bachem Holding AG stock faces operational push amid peptide market expansion and biotech demand surg  AD HOC NEWS
Source →
regulatory 2026-03-24
Bachem Holding AG stock faces biotech sector headwinds amid peptide market slowdown in 2026 - AD HOC NEWS
Bachem Holding AG stock faces biotech sector headwinds amid peptide market slowdown in 2026  AD HOC NEWS
Source →
general 2026-03-24
Bachem Holding AG Stock Gains Traction on SIX Swiss Exchange Amid Peptide Demand Surge - AD HOC NEWS
Bachem Holding AG Stock Gains Traction on SIX Swiss Exchange Amid Peptide Demand Surge  AD HOC NEWS
Source →
general 2026-03-24
Bachem Holding AG Stock Gains Traction on SIX Swiss Exchange Amid Peptide Demand Surge - AD HOC NEWS
Bachem Holding AG Stock Gains Traction on SIX Swiss Exchange Amid Peptide Demand Surge  AD HOC NEWS
Source →
general 2026-03-18
Berenberg Sticks With Bachem After A Strong 2025 - Finimize
Berenberg Sticks With Bachem After A Strong 2025  Finimize
Source →
general 2026-03-16
Bachem Holding AG stock under scrutiny as peptide cycle and order trends test patience - AD HOC NEWS
Bachem Holding AG stock under scrutiny as peptide cycle and order trends test patience  AD HOC NEWS
Source →
general 2026-03-16
Bachem Holding AG stock under scrutiny as peptide cycle and order trends test patience - AD HOC NEWS
Bachem Holding AG stock under scrutiny as peptide cycle and order trends test patience  AD HOC NEWS
Source →
regulatory 2026-03-14
Bachem posts surging sales and profit in 2025 - Indian Chemical News
Bachem posts surging sales and profit in 2025  Indian Chemical News
Source →
general 2026-03-12
Bachem Reports Strong Sales Growth and Sustained High Profitability - Barchart
Bachem Reports Strong Sales Growth and Sustained High Profitability  Barchart
Source →
general 2026-03-12
Bachem Reports Strong Sales Growth and Sustained High Profitability - BioSpace
Bachem Reports Strong Sales Growth and Sustained High Profitability  BioSpace
Source →
general 2026-03-06
Bachem Holding AG (CH0012530207): What Peptide Specialist Investors Need to Know in 2026 - AD HOC NEWS
Bachem Holding AG (CH0012530207): What Peptide Specialist Investors Need to Know in 2026  AD HOC NEWS
Source →
financial 2026-03-05
Bachem (BCHMF) to Release Quarterly Earnings on Thursday - Defense World
Bachem (BCHMF) to Release Quarterly Earnings on Thursday  Defense World
Source →
general 2026-03-03
Bachem (OTCMKTS:BCHMF) Trading 26.9% Higher – Should You Buy? - Defense World
Bachem (OTCMKTS:BCHMF) Trading 26.9% Higher – Should You Buy?  Defense World
Source →
general 2026-02-16
The Truth About Bachem Holding AG: Why Biotech Investors Are Suddenly Obsessed - AD HOC NEWS
The Truth About Bachem Holding AG: Why Biotech Investors Are Suddenly Obsessed  AD HOC NEWS
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Oligonucleotide CDMOs →

Similar CDMOs

Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
Signal Score: 83.5
Oligonucleotide, Biologics, AAV
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 81.6
mRNA, Oligonucleotide, Biologics
Nitto Denko Avecia
Milford, MA
Signal Score: 80.3
Oligonucleotide, mRNA
Kaneka Eurogentec
Seraing, BE
Signal Score: 80.3
mRNA, Plasmid, Oligonucleotide
Curia (RNA/Advanced)
Albany, NY · Albuquerque, NM
Signal Score: 79.4
mRNA, Oligonucleotide, Biologics